Commercialization of Human Mammary Basal / Luminal Cell System for Research

人类乳腺基底/腔细胞系统的商业化研究

• 批准号: 7608598
• 负责人: BENJAMIN M BUEHRER
• 金额: $ 20.66万
• 依托单位: ZEN-BIO, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608598
• 关键词: Address; Adipose tissue; Area; Basal Cell; Biological Assay; Biological Markers; Biological Models; Biotechnology; Breast; Cell Line; Cell Separation; Cells; Coculture Techniques; Commercial Sources; Communities; Condition; Contract Services; Contracts; Cryopreservation; Cultured Cells; Cytokeratin; Cytokine Gene; Data; Development; Diagnosis; Ductal Epithelial Cell; Epithelial Cells; Epithelium; Etiology; Freezing; Funding; Future; Gene Expression; Gland; Goals; Growth; Health Services Research; Human; Individual; Lead; Lobular; Longevity; Malignant - descriptor; Malignant Neoplasms; Mammary Gland Parenchyma; Mammary Neoplasms; Mammary gland; Marketing; Methods; Milk; Modeling; Numbers; Pharmacologic Substance; Phase; Phenotype; Population; Positioning Attribute; Preclinical Drug Evaluation; Preparation; Procedures; Process; Production; Property; Protocols documentation; Public Health; Quality Control; Reagent; Research; Research Contracts; Research Infrastructure; Research Personnel; Services; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Standards of Weights and Measures; Structure; Support System; Supporting Cell; System; Time; Tissue Procurements; Tissues; Variant; Woman; anticancer research; base; cell population study; cell type; commercialization; cost effective; cytokine; cytotoxicity; experience; human tissue; indexing; malignant breast neoplasm; neoplastic cell; novel; programs; systems research; Address; Adipose tissue; Area; Basal Cell; Biological Assay; Biological Markers; Biological Models; Biotechnology; Breast; Cell Line; Cell Separation; Cells; Coculture Techniques; Commercial Sources; Communities; Condition; Contract Services; Contracts; Cryopreservation; Cultured Cells; Cytokeratin; Cytokine Gene; Data; Development; Diagnosis; Ductal Epithelial Cell; Epithelial Cells; Epithelium; Etiology; Freezing; Funding; Future; Gene Expression; Gland; Goals; Growth; Health Services Research; Human; Individual; Lead; Lobular; Longevity; Malignant - descriptor; Malignant Neoplasms; Mammary Gland Parenchyma; Mammary Neoplasms; Mammary gland; Marketing; Methods; Milk; Modeling; Numbers; Pharmacologic Substance; Phase; Phenotype; Population; Positioning Attribute; Preclinical Drug Evaluation; Preparation; Procedures; Process; Production; Property; Protocols documentation; Public Health; Quality Control; Reagent; Research; Research Contracts; Research Infrastructure; Research Personnel; Services; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Standards of Weights and Measures; Structure; Support System; Supporting Cell; System; Time; Tissue Procurements; Tissues; Variant; Woman; anticancer research; base; cell population study; cell type; commercialization; cost effective; cytokine; cytotoxicity; experience; human tissue; indexing; malignant breast neoplasm; neoplastic cell; novel; programs; systems research

DESCRIPTION (provided by applicant): Breast cancer is the second most common cancer among women. Roughly 180,000 women in the U.S. will be diagnosed with malignant breast cancer in 2007-some 40,000 will die. The majority of breast cancers originate in the lobular or ductal cells of the milk-producing glands. In these structures, there are two main cell types: the inner luminal cells surrounded by basal myoepithelium. These cells types are distinct and are the precursors to various forms of breast cancer. As such, it is it is important to study these cell populations independently as well as in co-culture models systems. Current methods for culturing human mammary epithelial cells predominantly select for those of a basal phenotype. Thus, there are no commercial sources of quality-controlled, matched basal and luminal cells (from individual donors) in the U.S., forcing researchers to isolate and characterize the cells on their own. This process is time-consuming, requires access to human tissue, and introduces variation in the preparation and characterization of the cells. Primary cultured human mammary-derived cells are an ideal model currently used to investigate the genesis and understanding of human breast cancer. Because a consistent commercial source of primary human cultured breast-derived luminal and basal cells is unavailable, Zen-Bio, Inc. will address this need by providing a well characterized system to the research community. Phase I of this project focuses on generating an optimized primary human mammary-derived basal/luminal cell system. The Specific Aim is to optimize the isolation and propagation of human mammary epithelial cells followed by characterization of the cellular phenotypes. Optimization of the isolation and propagation will be achieved by systematically modifying aspects of existing protocols to enhance viable cell yields while minimizing population doublings. A detailed analysis of cell properties, including longevity in culture, cell specific gene expression, and cytokeratin production will be performed to initially validate the cell system. These analyses will form the basis of future quality control procedures. Phase II of this project contains two Specific Aims that will generate additional contract services at Zen-Bio. Aim I is to analyze the cytokine and gene expression differences between the two cell types Completion of this Aim leads directly to Aim II which is to establish contract research services at Zen-Bio for those in both the academic as well as pharmaceutical arenas . These services include analysis of cytokine secretion, gene expression, tumor cell(s)-adipose interaction, and cytotoxicity. Multiple product offerings are expected from this proposal: a matched, primary human mammary cell system, support media and reagents, contract assay services, and kits for basal/luminal cell research. PUBLIC HEALTH RELEVANCE: At the completion of this project, a commercially available, fully characterized human, primary mammary- derived basal/luminal cell system and support reagents will be offered to researchers. The accessibility of this currently unavailable system will not only provide a greater opportunity to investigate novel methods to further understand the etiology of breast cancer but also to investigate potential cures.

描述（由申请人提供）：乳腺癌是女性中第二常见的癌症。在2007年，有40,000名在美国大约有18万名妇女将被诊断出患有恶性乳腺癌。大多数乳腺癌起源于产牛奶的腺体的小叶或导管细胞。在这些结构中，有两种主要的细胞类型：内腔细胞被基底肌上皮包围。这些细胞类型是不同的，是各种形式的乳腺癌的前体。因此，重要的是独立研究这些细胞种群以及共培养模型系统。当前培养人类乳腺上皮细胞的方法主要选择基础表型的方法。因此，没有商业来源的质量控制，匹配的基础和腔内细胞（来自个人捐助者），迫使研究人员独自分离和表征细胞。这个过程耗时，需要进入人体组织，并引入细胞的制备和表征变化。原发性培养的人类乳腺衍生细胞是目前用于研究人类乳腺癌的起源和理解的理想模型。由于不可用的原代人培养的乳腺腔和基底细胞的一致商业来源，因此Zen-Bio，Inc。将通过为研究界提供良好的系统来满足这一需求。该项目的第一阶段着重于生成优化的原代人乳腺衍生的基底/腔细胞系统。具体的目的是优化人类乳腺上皮细胞的分离和传播，然后表征细胞表型。通过系统地修改现有方案的方面以增强可行的细胞产量，同时最大程度地减少人口加倍，可以实现隔离和传播的优化。将对细胞特性进行详细分析，包括培养物中的寿命，细胞特异性基因表达和细胞角蛋白产生，以最初验证细胞系统。这些分析将构成未来质量控制程序的基础。该项目的第二阶段包含两个具体目标，这些目标将在Zen-Bio中产生额外的合同服务。目的I是分析此目标的两种细胞类型完成之间的细胞因子和基因表达差异直接导致AIM II，这是在Zen-Bio中为学术和药物领域的人建立合同研究服务。这些服务包括分析细胞因子分泌，基因表达，肿瘤细胞 - 脂肪相互作用和细胞毒性。该提案预计会提供多种产品：一种匹配的原代人类乳细胞系统，支持培养基和试剂，合同测定服务以及基础/腔内细胞研究的套件。公共卫生相关性：该项目完成后，将向研究人员提供商业上可获得的，完全表征的人类，原发性乳腺衍生的基础/腔细胞系统和支持试剂。当前无法使用的系统的可及性不仅将为研究新的方法提供更多的机会，以进一步了解乳腺癌的病因，而且还可以研究潜在的治疗方法。